Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Resistant Pseudomos aeruginosa Infections - Overview
Resistant Pseudomos aeruginosa Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Resistant Pseudomos aeruginosa Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Resistant Pseudomos aeruginosa Infections - Companies Involved in Therapeutics Development
AMR Centre Ltd
Armata Pharmaceuticals Inc
Biolytics Pharma
Boston Pharmaceuticals Inc
Inhibrx Inc
Lineus Bioscience Inc
Shionogi & Co Ltd
VetoRx Pharmaceuticals Inc
Resistant Pseudomos aeruginosa Infections - Drug Profiles
(cefepime + taniborbactam hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ciprofloxacin + colistimethate sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APPA-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Multi-Drug Resistant Pseudomos aeruginosa Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Pseudomos Aeruginosa Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Resistant Pseudomos aeruginosa Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefiderocol sulfate tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COT-143 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INBRX-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEG-2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pseudomos aeruginosa Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Resistant Pseudomos aeruginosa Infections - Dormant Projects
Resistant Pseudomos aeruginosa Infections - Product Development Milestones
Featured News & Press Releases
Apr 18, 2018: Shionogi to Present New Data on COT-143 at 2018 European Congress of Clinical Microbiology and Infectious Diseases
Oct 31, 2017: Inhibrx Wins CARB-X Award Of Up To $6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomos Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Resistant Pseudomonas aeruginosa Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by AMR Centre Ltd, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by Armata Pharmaceuticals Inc, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by Boston Pharmaceuticals Inc, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by Inhibrx Inc, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by Linnaeus Bioscience Inc, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd, H2 2020
Resistant Pseudomonas aeruginosa Infections - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2020
Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H2 2020
Resistant Pseudomonas aeruginosa Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020